Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RAS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    340 result(s) found for: RAS. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-002849-11 Sponsor Protocol Number: FIRE-5 Start Date*: 2019-06-17
    Sponsor Name:Klinikum der Universität München, Ludwig-Maximilians-Universität München, represented by the managing medical director
    Full Title: Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation
    Medical condition: RAS-mutant metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006312-38 Sponsor Protocol Number: SAKK 41/08 Start Date*: 2009-08-05
    Sponsor Name:SAKK (Swiss Group for Clinical Cancer Research)
    Full Title: Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial.
    Medical condition: Advanced K-ras mutated rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002037-38 Sponsor Protocol Number: NL44415.078.13 Start Date*: 2013-10-29
    Sponsor Name:
    Full Title: The effect of correction of metabolic acidosis in chronics kidney disease on intrarenal RAS activity.
    Medical condition: Metabolic acidosis in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006012-38 Sponsor Protocol Number: SAKK 41/07 Start Date*: 2009-08-04
    Sponsor Name:SAKK (Swiss Group for Clinical Cancer Research)
    Full Title: Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial.
    Medical condition: Advanced K-ras unmutated rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000250-55 Sponsor Protocol Number: RASQAL Start Date*: 2012-07-12
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für innere Medizin III
    Full Title: Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
    Medical condition: - Chronic kidney disease stages III-IV (defined by MDRD formula) - Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012655-26 Sponsor Protocol Number: HE 6A/09 Start Date*: 2010-07-13
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS
    Medical condition: Wild-type K-ras metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002175-34 Sponsor Protocol Number: EPOCH Start Date*: 2012-10-23
    Sponsor Name:Med. Univ. Wien, Universitätsklinik f. Innere Medizin III, Abt. f. Nephrologie und Dialyse
    Full Title: Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients with Hypertension (EPOCH)
    Medical condition: proteinuric patients suffering from chronic kidney disease (II - III) ,diabetes mellitus II and hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003242-25 Sponsor Protocol Number: GITuD-20172019 Start Date*: 2018-03-02
    Sponsor Name:ASOCIACION GITuD
    Full Title: Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFO...
    Medical condition: Wild-type RAS metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014876-23 Sponsor Protocol Number: EZN-2208-04 Start Date*: 2010-05-20
    Sponsor Name:Enzon Pharmaceuticals, Inc
    Full Title: A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)
    Medical condition: mestatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014041-81 Sponsor Protocol Number: 2906 Start Date*: 2009-11-13
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)
    Medical condition: k-ras wild type metastatic colorectal cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017384-42 Sponsor Protocol Number: 838 Start Date*: 2010-05-17
    Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum
    Full Title: Safety and efficacy of the addition of simvastatin to cetuximab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage ...
    Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5-FU, oxaliplatin, and irinotecan containing regimens.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061451 Colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004683-30 Sponsor Protocol Number: KRAS2011 Start Date*: 2012-05-02
    Sponsor Name:VU University Medical
    Full Title: A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation
    Medical condition: Patients with advanced non small cell lung cancer that harbours a K-Ras mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003778-29 Sponsor Protocol Number: CIFRA Start Date*: 2019-03-06
    Sponsor Name:Istituto Nazionale Tumori G. Pascale
    Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V
    Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004593-56 Sponsor Protocol Number: CAVE-2 Start Date*: 2022-05-19
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
    Medical condition: Pre-treated RAS/BRAF wild type metastatic colorectal cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012040-16 Sponsor Protocol Number: EMR62242–004 Start Date*: 2009-10-06
    Sponsor Name:Merck KGaA
    Full Title: An open-label, randomized, controlled, multi-center, Phase I/II trial investigating 2 EMD 525797 doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line...
    Medical condition: Subjects with k-ras WT, metastatic colorectal cancer who have failed a fist line chemotherapy with an oxaliplatin-containing regimen will be eligible for this trial.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) CZ (Completed) GB (Completed) HU (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011882-10 Sponsor Protocol Number: GETUG-AFU 19/0901 Start Date*: 2010-02-26
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mu...
    Medical condition: Advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001328-36 Sponsor Protocol Number: na Start Date*: 2020-04-22
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the ...
    Medical condition: patients with RAS-mt mCRC at diagnosis (based on tumor tissue) who convert to RAS-wt disease (based on ctDNA) at progression after first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079136 Adenocarcinoma of colon metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001381-11 Sponsor Protocol Number: APHP200409 Start Date*: 2020-04-08
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: ...
    Medical condition: Adult patients with a diagnosis of COVID-19 requiring hospitalization in a non-ICU and on prior therapy with RAS blockers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003008-15 Sponsor Protocol Number: CAPRI2 Start Date*: 2021-05-27
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.
    Medical condition: mCRC patients with RAS/BRAF wild type tumors at start of first line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:44:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA